Nuvectis Pharma, Inc. (NVCT)

NCM – Цена в реальном времени. Валюта: USD

10.90

-0.16 (-1.45%)

При закрытии: May 12, 2026, 4:00 PM EDT

11.06

+0.16 (1.47%)

До открытия: May 13, 2026, 7:37 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Nuvectis Pharma, Inc. (NVCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Nuvectis Pharma, Inc. (NVCT)

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Видео

No Data

Пресс-релизы

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Search stocks

Nuvectis Pharma, Inc. (NVCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Nuvectis Pharma, Inc. (NVCT)

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Видео

No Data

Пресс-релизы

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC